Incannex Healthcare Executes 1-for-30 Reverse Split to Preserve Nasdaq Listing
Incannex Healthcare implemented a 1-for-30 reverse stock split effective February 26, 2026, regaining compliance with Nasdaq’s minimum bid-price requirement and preserving its listing; trading begins February 27 under a new CUSIP. The board appointed MDs Murray Stein, Andrew Cutler and Amir Kalali to its Clinical Advisory Board.
1. Reverse Split to Regain Nasdaq Compliance
Incannex Healthcare’s board approved a 1-for-30 reverse stock split to take legal effect at 4:01 p.m. ET on February 26, 2026. The measure aims to restore the company’s minimum bid-price compliance with Nasdaq rules and maintain its listing status, with split-adjusted trading commencing February 27 under a new CUSIP on the Nasdaq Capital Market.
2. Expansion of Clinical Advisory Board
The company added three physicians—Murray Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD—to its Clinical Advisory Board. This board will provide independent scientific and clinical guidance on PSX-001’s trial design, endpoint selection and regulatory strategy as Incannex advances its lead therapeutic through clinical development.